Author

Andrew W. Lindsley

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Real-World Impact of Tezepelumab on Asthma Exacerbations, Healthcare Resource Utilization, and Costs in US Patients with Severe Asthma: CROSSROADS-1

Purpose Asthma affects 26 million individuals in the US, with severe cases driving high healthcare use and costs. TezspireTM (tezepelumab) has shown benefits in a Phase 4 real-world study, but real-world claims-based evidence is limited. This study evaluated the real-world effectiveness of tezepelumab by assessing chan...

Santiago Zuluaga Sanchez, J. Demartino, M. Gorritz et al. · Journal of Asthma and Allerg... · 0 citations

Open access Sep 2026

Assessing the impact of earlier initiation of biologics on clinical remission and other outcomes in a global real-life severe asthma cohort from CHRONICLE, ISAR and OPCRD.

BACKGROUND Biologics are generally reserved for severe asthma (SA) after standard treatments have failed. Their recommendation is based on randomized controlled trials, designed to assess efficacy but not the optimal timing for biologic initiation. RESEARCH QUESTION Does the timing of biologic initiation affect SA ou...

G. Canonica, G. Christoff, Ming-Ju Tsai et al. · Chest · 0 citations

Review Open access Sep 2026

Lessons learned from clinical trials of thymic stromal lymphopoietin (TSLP) inhibition.

Type 2 (T2) immune-mediated epithelial-driven diseases are characterized by dysregulated immune responses at epithelial barrier surfaces. A key mediator of these diseases is thymic stromal lymphopoietin (TSLP), an epithelial cytokine that acts as a regulator of both T2 and non-T2 inflammation. TSLP activates dendritic...

J. Corren, L. Borish, C. Brightling et al. · Journal of Allergy and Clini... · 0 citations